La vendita allo scoperto per Lexaria Bioscience dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Lexaria Bioscience. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Lexaria Bioscience (NASDAQ:LEXX) Azioni, Report sulle vendite allo scoperto

Lexaria Bioscience

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.

Lexaria Bioscience Corp

Outlook
ACM has raised its revenue guidance range for fiscal year 2024 to a range of $725 million to $745 million from the prior range of $695 million to $735 million.

News

Guidance

ACMR

ACM Research Expects FY24 Revenue Of $725M-$745M (Prior $695M-$735M) Vs $728.43M Est

Needham analyst David Saxon reiterates Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) with a Hold.

Reiteration

Analyst Ratings

GMED

Needham Reiterates Hold on Globus Medical

Yaniv Arieli, Chief Financial Officer of Ceva, stated: "Our robust third quarter earnings more than doubled our non-GAAP net income and diluted income per share year-over-year. For the full year, we now expect overall revenues to be higher than previous guidance, at a new range of 7%-9% growth, enabling us to double our non-GAAP fully diluted EPS year-over-year. We continued to buy back the company's stock during the quarter, repurchasing approximately 186,000 shares for approximately $4.2 million under our stock repurchase program. Furthermore, the Ceva Board of Directors today authorized the expansion of the company's share repurchase program with an additional 700,000 shares of common stock available for repurchase, bringing the total shares available for repurchase to approximately 1 million. At the end of the quarter, our cash and cash equivalent balances, marketable securities and bank deposits were approximately $158 million, ensuring we are well-positioned to explore opportunities for non-organic growth."

CEVA

Ceva Expects FY24 Revenue Growth Of 7%-9% Enabling It It Double Its Adj EPS

Needham analyst Serge Belanger reiterates NewAmsterdam Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>) with a Buy and maintains $36 price target.

Price Target

NAMS

Needham Reiterates Buy on NewAmsterdam Pharma, Maintains $36 Price Target

Mitsubishi Estate Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MITEY#OTC">MITEY</a>) reported quarterly earnings of $0.13 per share. This is a 8.33 percent increase over earnings of $0.12 per share from the same period last year. The company reported $2.10 billion in sales this quarter. This is a 5.10 percent increase over sales of $2.00 billion the same period last year.

Earnings

MITEY

Mitsubishi Estate Co Q2 EPS $0.13 Up From $0.12 YoY, Sales $2.10B Up From $2.00B YoY

Legrand (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LGRVF#OTC">LGRVF</a>) reported quarterly earnings of $1.07 per share. This is a 6.96 percent decrease over earnings of $1.15 per share from the same period last year. The company reported $2.22 billion in sales this quarter. This is a 1.23 percent increase over sales of $2.19 billion the same period last year.

LGRVF

Legrand Q3 EPS $1.07 Down From $1.15 YoY, Sales $2.22B Up From $2.19B YoY

Needham analyst Gil Blum maintains Immunocore Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCR#NASDAQ">IMCR</a>) with a Buy and lowers the price target from $78 to $71.

IMCR

Needham Maintains Buy on Immunocore Hldgs, Lowers Price Target to $71

FUJIFILM Holdings (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUJIY#OTC">FUJIY</a>) reported quarterly earnings of $0.28 per share. This is a 64.71 percent increase over earnings of $0.17 per share from the same period last year. The company reported $5.14 billion in sales this quarter. This is a 2.14 percent increase over sales of $5.04 billion the same period last year.

FUJIY

FUJIFILM Holdings Q2 EPS $0.28 Up From $0.17 YoY, Sales $5.14B Up From $5.04B YoY

KBC Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KBCSY#OTC">KBCSY</a>) reported quarterly earnings of $1.18 per share. This is a 4.42 percent increase over earnings of $1.13 per share from the same period last year. The company reported $3.06 billion in sales this quarter. This is a 3.65 percent increase over sales of $2.96 billion the same period last year.

KBCSY

KBC Group Q3 EPS $1.18 Up From $1.13 YoY, Sales $3.06B Up From $2.96B YoY

Munchener (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MURGY#OTC">MURGY</a>) reported quarterly earnings of $0.19 per share which missed the analyst consensus estimate of $0.20 by 5 percent. This is unchanged from the same period last year. The company reported quarterly sales of $15.89 billion which missed the analyst consensus estimate of $16.15 billion by 1.59 percent. This is a 0.98 percent increase over sales of $15.74 billion the same period last year.

MURGY

Munchener Q3 EPS $0.19 Misses $0.20 Estimate, Sales $15.89B Miss $16.15B Estimate

Announced at Fal.Con Europe, CrowdStrike's inaugural premier user conference in the region, this latest expansion builds on CrowdStrike and Ignition's success in the UK and Nordics – growing their regional partner business more than 85% year-over-year – by driving customer demand for cybersecurity transformation, platform adoption and vendor consolidation.&nbsp;

Contracts

General

CRWD

CrowdStrike Announced An Expanded Distribution Partnership With Ignition Technology, Bringing The CrowdStrike Falcon Cybersecurity Platform To Ignition's Partner Base In Ireland.

Ceva, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEVA#NASDAQ">CEVA</a>), the leading licensor of silicon and software IP that enables Smart Edge devices to connect, sense and infer data more reliably and efficiently, today announced that its Board of Directors authorized the expansion of the company's share repurchase program with an additional 700,000 shares of common stock available for repurchase. As of September 30, 2024, Ceva had approximately 356,000 shares of common stock available for repurchase under the existing plan, bringing the aggregate to approximately 1,056,000 shares available for repurchase.

Buybacks

Ceva's Board Approved Expansion Of Buyback Program By Additional 700K Shares

The Ultra C Tahoe now achieves the performance of standalone single-wafer cleaning tools on low-to-medium temperature sulfuric peroxide mix (SPM) processes. Tahoe's patented hybrid architecture is among the first in the industry to combine batch wafer processing and single wafer cleaning chambers into the same SPM tool. The hybrid architecture delivers enhanced cleaning performance, high throughput, and process flexibility, with up to 75% reduction in chemical consumption. ACM estimates cost savings of up to $500,000 per year from sulfuric acid alone, with additional environmental and cost benefits from reduced sulfuric acid treatment and disposal.

Tech

ACM Research Announced A Major Performance Breakthrough For Its Flagship Ultra C Tahoe Cleaning Tool, To Meet Technical Requirements Of Advanced Nodes For Foundry, Logic And Memory Applications For Front-end Semiconductor Manufacturing

Needham analyst Mike Matson reiterates Enovis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>) with a Buy and maintains $65 price target.

ENOV

Needham Reiterates Buy on Enovis, Maintains $65 Price Target

Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) has partnered with Hugging Face to advance robotics research and development using open-source <a href="https://www.benzinga.com/topic/artificial-intelligence">artificial intelligence technology</a>.
What Happened: At the Conference for Robot Learning (CoRL) in Munich, Germany, Hugging Face and Nvidia <a href="https://blogs.nvidia.com/blog/hugging-face-lerobot-open-source-robotics/">announced</a> a collaboration to expedite robotics research and development by uniting their open-source robotics communities.
This collaboration will combine Hugging Face&#8217;s LeRobot open AI platform with Nvidia&#8217;s AI, Omniverse, and Isaac robotics technology to drive advancements across various industries, including manufacturing, healthcare, and logistics.
The LeRobot platform will provide a comprehensive suite of tools for sharing data collection, model training, and simulation environments, along with designs for low-cost manipulator kits. 
Nvidia&#8217;s AI technology, simulation, and open-source robot learning modular framework, such as NVIDIA Isaac Lab, will accelerate LeRobot&#8217;s data collection, training, and verification workflow.
See Also: <a href="https://www.benzinga.com/markets/equities/24/11/41767332/trumps-potential-return-to-white-house-sends-ex-president-linked-phunware-stock-upwards-during-p?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump&#8217;s Potential Return To White House Sends Ex-President Linked Phunware Stock Upwards During Pre-Market Hours</a>
Why It Matters: Earlier in May, Hugging Face had partnered with Amazon.com Inc. to simplify running <a href="https://www.benzinga.com/news/24/05/38990924/amazon-and-ai-startup-hugging-face-partner-to-enhance-ai-model-efficiency">thousands of AI models</a> on Amazon&#8217;s custom computing chips. This partnership aimed to enhance AI model efficiency on Amazon Web Services (AWS) custom chip called Inferentia2.
Meanwhile, Nvidia&#8217;s new free, open-source AI model, Llama-3.1-Nemotron-70B-Instruct, has <a href="https://www.benzinga.com/news/24/10/41422278/nvidias-new-free-open-source-ai-model-reportedly-outperforms-openais-gpt-4o-anthropics-claude-3-5-so">reportedly outperformed its competitors</a> in benchmark tests. This model, built on Meta Platforms Inc.&#8216;s Llama 3.1 framework, has surpassed larger models in benchmark tests.
Back in August 2023, Hugging Face, a Nvidia-backed open-source AI startup, <a href="https://www.benzinga.com/news/23/08/34042661/nvidia-backed-open-source-ai-startup-reaches-4-5b-valuation-with-tech-titans-support">reached a $4.5 billion valuation</a> with the support of tech titans. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/41734887/cathie-woods-latest-shake-up-dumps-palantir-and-jack-dorseys-block-along-with-tesla-buys-amazon-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Cathie Wood&#8217;s Latest Shake-up: Dumps Palantir And Jack Dorsey&#8217;s Block Along With Tesla, Buys Amazon And Meta</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Startups

AMZN

NVDA

Nvidia Partners With AI Startup Hugging Face To Supercharge Open Source Robotics

Earnings Beats

ACM Research Q3 2024 Adj. EPS $0.63 Beats $0.37 Estimate, Sales $203.976M Beat $191.176M Estimate

CEVA Q3 2024 Adj. EPS $0.14 Beats $0.10 Estimate, Sales $27.207M Beat $26.850M Estimate

Needham analyst Laura Martin reiterates Perion Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PERI#NASDAQ">PERI</a>) with a Hold.

PERI

Needham Reiterates Hold on Perion Network

Virgin Galactic Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NYSE">SPCE</a>) shares closed up 3.5% on Wednesday after the company reported a net loss of $75 million for the third quarter, lower than the $105 million net loss reported in the corresponding period last year owing to lower operating expenses.
What Happened: Branson&#8217;s spaceflight company&#8217;s total operating expenses fell to $82.1 million in the third quarter from $116 million in the corresponding quarter a year ago. However, revenue also fell to $0.4 million from $1.7 million last year owing to the pause in commercial spaceflights.
Virgin Galactic is now focussing its efforts on the production of the Delta Class spaceships. The new spaceships remain on track to enter commercial service in 2026, the company said.
Delta Class will&nbsp;<a href="https://www.benzinga.com/news/24/06/39247906/planes-just-cant-compete-elon-musk-boasts-rocket-booster-superiority-after-richard-bransons-virgin-g" target="_blank" rel="noreferrer noopener">replace the company's VSS Unity spaceplane</a>&nbsp;which had its last commercial flight in the second quarter. 
Announces At-The-Market Equity Program: Virgin Galactic on Wednesday also said that it entered into a sales agreement under which it may offer and sell shares of its common stock having an aggregate offering price of up to $300 million from time to time pursuant to an "at the market" program.
The proceeds from the program, it said, will be used to accelerate the development and production of its next-generation spaceflight fleet, including an additional carrier plane such as the company&#8217;s VMS Eve dual fuselage jet carrier aircraft and third and fourth Delta Class spaceships.
Price Action: Virgin Galactic shares closed up 3.5% on Wednesday at $7.12. The stock, however, is down by about 85% year-to-date, according to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="650" height="450" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07041713/newplot-15.jpeg" alt="" class="wp-image-634803" style="width:920px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07041713/newplot-15.jpeg 650w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07041713/newplot-15-300x208.jpeg 300w" sizes="(max-width: 650px) 100vw, 650px" /></figure>
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41767169/spacex-completes-400th-successful-falcon-launch-to-date-but-will-miss-target-of-144-launches-in-2024" target="_blank" rel="noreferrer noopener">SpaceX Completes 400th Successful Falcon Launch To Date, But Will Miss Target Of 144 Launches In 2024, Says Company Exec</a></li>
</ul>
Photo courtesy: Shutterstock

SPACE

SPCE

Richard Branson's Spaceflight Startup Virgin Galactic Sees Stock Surge After Narrowing Q3 Losses, Announces $300M Stock Sale

Needham analyst Joshua Reilly maintains Vertex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERX#NASDAQ">VERX</a>) with a Buy and raises the price target from $45 to $60.

VERX

Needham Maintains Buy on Vertex, Raises Price Target to $60

Lexaria Bioscience (LEXX) has released an update. Lexaria Bioscience Corp. is set to begin a human pilot study to test the oral delivery of tirzepa...

Lexaria Advances Oral Diabetes Treatment Study

Lexaria Bioscience (LEXX) has released an update. Lexaria Bioscience Corp. has appointed Michael Shankman as its new Chief Financial Officer, marki...

Lexaria Bioscience Welcomes New CFO Amid Growth

Lexaria Bioscience (LEXX) has released an update. Lexaria Bioscience Corp. reports rapid growth in the GLP-1 market, with significant dominance by ...

Lexaria Foresees Lead in Booming GLP-1 Market

Lexaria Bioscience (LEXX) has released an update. Lexaria Bioscience has launched a new human pilot study to evaluate the oral administration of De...

Lexaria Tests Oral Alternative for Billion-Dollar Injection Drug

Lexaria Bioscience announces $5M securities offering

Lexaria Bioscience (LEXX) has released an update. Lexaria Bioscience has announced a $5 million registered direct offering, pricing its shares at-t...

Lexaria Bioscience's $5 Million Direct Offering

Lexaria Bioscience (LEXX) has received partial 12-week body weight results from the recently completed animal study WEIGHT-A24-1. Lexaria is "stron...

Lexaria Bioscience announces partial 12-week results from WEIGHT-A24-1 study

Lexaria Bioscience (LEXX) has released an update. Lexaria Bioscience's recent animal study reveals promising 12-week results for its DehydraTECH-li...

Lexaria Bioscience Reports Promising Weight Loss Study

Lexaria Bioscience (LEXX) received partial 12-week blood sugar results from the recently completed animal study WEIGHT-A24-1. The company said, "Le...

Lexaria announces partial 12-week blood sugar results from GLP-1 diabetes study

Lexaria Bioscience (LEXX) has released an update. Lexaria Bioscience has reported promising results from its diabetes animal study, revealing that ...

Comments

Lexaria Bioscience

Vendite allo scoperto

Lexaria Bioscience (NASDAQ:LEXX) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO